Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Pro Medicus (ASX:PME) share price jumps on Apple Vision Pro update

The Pro Medicus Ltd (ASX:PME) share price has gone up 4% after the ASX healthcare share revealed Visage Ease VP for Apple Vision Pro.

The Pro Medicus Ltd (ASX: PME) share price has gone up more than 4% after the ASX healthcare share revealed Visage Ease VP for Apple Vision Pro.

Pro Medicus describes itself as a healthcare informatics company which provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups.

Visage Ease VP for Apple Vision Pro

Pro Medicus has launched Visage Ease VP, which “supports immersive, spatial experiences for diagnostic imaging and multimedia.”

The company said its cinematic rendering engine provides “stunning volume-rendered images in immersive space.”

On-the-go access with Visage Ease VP has “additional flexibility with virtual screens at more than 4K resolution for each eye.” It uses the input of eyes, hands and voice navigation to provide an end-user imaging experience that’s unlike any other application.

Pro Medicus said UC San Diego Health, a tier 1 academic medical centre and Visage customer, is the first health system to pilot the technology.

The company pointed out that this new spatial imaging offering has the potential to open up a number of “novel and exciting possibilities within both medical imaging and the wider healthcare space.”

Comments

Dr. Paul Murphy, associate clinical professor at UC San Diego School of Medicine and radiologist at UC San Diego Health said:

The visualization of three-dimensional medical imaging in immersive space creates exciting opportunities to improve patient care.

Technology that allows for sophisticated eye motion and gesture controls for reviewing 2D and 3D medical imaging could potentially help in efficient tumor board reviews and create collaborative spaces in healthcare.

Final thoughts on the Pro Medicus share price

The company has a pleasing habit of announcing good news, and this seems to have excited the market again. It’s good to see the company is thinking about the future and able to tap into the latest technology.

At a share price of close to $110, it has an enormous amount of profit growth assumed in the valuation. Is it a good idea that the price/earnings ratio (p/e ratio) keeps rising?

It has looked expensive for a long time, and yet it keeps rising. It’s probably the best business on the ASX, and it’s certainly priced that way.

There are other ASX growth shares I’d rather invest in at the current price.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content